Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Untch M, Eidtmann H, du Bois A, Meerpohl HG, Thomssen Ch, Ebert A, Harbeck N, Jackisch C, Heilman V, Emons G, Wallwiener D, Wiese W, Blohmer JU, Höffken K, Kuhn W, Reichardt P, Muscholl M, Pauschinger M, Langer B, Lück HJ. Untch M, et al. Among authors: eidtmann h. Eur J Cancer. 2004 May;40(7):988-97. doi: 10.1016/j.ejca.2004.01.011. Eur J Cancer. 2004. PMID: 15093573 Clinical Trial.
Anthracycline and trastuzumab in breast cancer treatment.
Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG, Thomssen C, Harbeck N, Jackisch C, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B. Untch M, et al. Among authors: eidtmann h. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):59-64. Oncology (Williston Park). 2004. PMID: 15685838 Free article. Clinical Trial.
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer JU, Tesch H, Gerber B, Höß C, Kümmel S, Mau C, Jackisch C, Khandan F, Costa SD, Krabisch P, Loibl S, Nekljudova V, Untch M, Minckwitz Gv. Huober J, et al. Among authors: eidtmann h. Eur J Cancer. 2013 Jul;49(10):2284-93. doi: 10.1016/j.ejca.2013.02.027. Epub 2013 Mar 27. Eur J Cancer. 2013. PMID: 23541564 Clinical Trial.
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G. Lück HJ, et al. Among authors: eidtmann h. Breast Cancer Res Treat. 2013 Jun;139(3):779-87. doi: 10.1007/s10549-013-2589-8. Epub 2013 Jun 15. Breast Cancer Res Treat. 2013. PMID: 23771714 Clinical Trial.
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F, Lederer B, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kümmel S, Loibl S, Paepke S, Untch M, von Minckwitz G, Schneeweiss A. Marmé F, et al. Among authors: eidtmann h. Eur J Cancer. 2016 Jan;53:65-74. doi: 10.1016/j.ejca.2015.09.022. Epub 2015 Dec 13. Eur J Cancer. 2016. PMID: 26693900
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ. Konecny GE, et al. Among authors: eidtmann h. J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51. doi: 10.1093/jnci/djh198. J Natl Cancer Inst. 2004. PMID: 15292386
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, Engels K, Burchardi N, von Minckwitz G. Hanusch C, et al. Among authors: eidtmann h. Clin Cancer Res. 2015 Jul 1;21(13):2924-31. doi: 10.1158/1078-0432.CCR-14-2774. Epub 2015 Mar 30. Clin Cancer Res. 2015. PMID: 25825476 Clinical Trial.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Piccart-Gebhart M, et al. Among authors: eidtmann h. J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598744 Free PMC article. Clinical Trial.
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M. von Minckwitz G, et al. Among authors: eidtmann h. Ann Oncol. 2014 Jan;25(1):81-9. doi: 10.1093/annonc/mdt410. Epub 2013 Nov 21. Ann Oncol. 2014. PMID: 24273046 Free article. Clinical Trial.
95 results